PCRX(Pacira BioSciences, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $541.53M | $666.82M | $674.98M | $700.97M | $726.41M |
| 毛利润 | $401.28M | $467.53M | $490.31M | $530.54M | $576.66M |
| 营业利润 | $89.92M | $60.02M | $87.67M | −$73.37M | $19.19M |
| 净利润 | $41.98M | $15.91M | $41.95M | −$99.56M | $7.03M |
| 经营现金流 | $125.72M | $145.27M | $154.65M | $189.39M | $151.99M |
| 自由现金流 | $79.85M | $115.20M | $139.49M | $178.75M | $136.66M |
| 摊薄每股收益 | $0.92 | $0.34 | $0.89 | $-2.15 | $0.16 |